Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Leukemia

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2402969PMID 12835719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progress with chronic myelogenous leukemia: a personal perspective over four decades.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Heterogenic molecular basis for loss of ABL1‐BCR transcription: Deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR‐ABL1‐positive chronic myeloid leukemia

  2002cited by this paper
• Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.

  2002cited by this paper
• Multicolor spectral karyotyping of serous ovarian adenocarcinoma

  2002cited by this paper
• Chromosomal imbalances of primary and metastatic lung adenocarcinomas

  2002cited by this paper
• Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily.

  2001cited by this paper
• ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.

  2001cited by this paper
• AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.

  2001cited by this paper
• ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.

  2001cited by this paper
• Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis.

  2001cited by this paper
• Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies.

  2001cited by this paper
• Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions.

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

  2000cited by this paper
• Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China.

  2000cited by this paper
• High frequency loss of heterozygosity in the region of the DBH locus in bladder cancer.

  2000cited by this paper
• Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping

  2000cited by this paper
• Recurrent chromosome aberrations in cancer.

  2000cited by this paper
• Diagnosis of haploidy and triploidy based on measurement of gene copy number by real‐time PCR

  2000cited by this paper
• Real-time quantitative polymerase chain reaction

  2000cited by this paper
• Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Suicidal differential housekeeping gene activity in apoptosis induced by DCNP

  2000cited by this paper
• Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.

  2000cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

  2000cited by this paper
• ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.

  1999cited by this paper
• ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.

  1999cited by this paper
• Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.

  1999cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy.

  1999cited by this paper
• TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency.

  1999cited by this paper
• Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.

  1999cited by this paper
• Gene dosage by quantitative real-time PCR.

  1999cited by this paper
• Chronic Myelogenous Leukemia: Biology and Therapy

  1999cited by this paper
• SET domain proteins modulate chromatin domains in eu- and heterochromatin

  1998cited by this paper
• Chronic myelogenous leukemia: molecular and cellular aspects

  1998cited by this paper
• Developments in Quantitative PCR

  1998cited by this paper
• Comparison of three RT-PCR methods.

  1998cited by this paper
• Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

  1997cited by this paper
• BCR/ABL induces multiple abnormalities of cytoskeletal function.

  1997cited by this paper
• Role of focal adhesion proteins in signal transduction and oncogenesis.

  1997cited by this paper
• The exosome: a conserved eukaryotic RNA processing complex containing multiple 3'-->5' exoribonucleases.

  1997cited by this paper
• Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.

  1997cited by this paper
• The 3' end of yeast 5.8S rRNA is generated by an exonuclease processing mechanism.

  1996cited by this paper
• Real time quantitative PCR.

  1996cited by this paper
• High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.

  1996cited by this paper
• Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.

  1995cited by this paper
• Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes

  1995cited by this paper
• BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.

  1995cited by this paper
• Interferon response in chronic myeloid leukaemia correlates with ABL/BCR expression: a preliminary study

  1995cited by this paper
• Catalog of chromosome aberrations in cancer (5th edn): by Felix Mitelman (Bertil Johansson and Fredrik Mertens associated eds) Wiley-Liss, 1994. £345.00 $518.00 (xxi + 4252 pages; 2 volumes) ISBN 0 471 11183 X

  1995cited by this paper
• Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors.

  1994cited by this paper
• Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.

  1994cited by this paper
• Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway.

  1994cited by this paper
• A coupled one-step reverse transcription PCR procedure for generation of full-length open reading frames.

  1994cited by this paper
• ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukaemia.

  1993cited by this paper
• The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia

  1993cited by this paper
• Clusters of chromosome 9 aberrations are associated with clinico‐pathologic subsets of non‐Hodgkin's lymphoma

  1993cited by this paper
• Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions

  1993cited by this paper
• The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.

  1993cited by this paper
• Staging and prognosis in chronic myelogenous leukemia.

  1988cited by this paper
• Definition of the accelerated phase of chronic myelogenous leukemia.

  1988cited by this paper
• Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

  1987cited by this paper
• Catalog of chromosome aberrations in cancer

  1985cited by this paper

• PRDM12 in Health and Diseases

  2021cites this paper
• VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer

  2021cites this paper
• Multifaceted Role of PRDM Proteins in Human Cancer

  2020cites this paper
• Understanding the Role of Prdm12b in Zebrafish Development

  2019cites this paper
• MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

  2018cites this paper
• Chronic myeloid leukemia

  2015cites this paper
• An emerging role for prdm family genes in dorsoventral patterning of the vertebrate nervous system

  2015cites this paper
• Context-specific regulation of cancer epigenomes by histone and transcription factor methylation

  2014cites this paper
• chronic myelogenous leukemia significance of deletions of derivative chromosome 9 in patients with Imatinib mesylate therapy may overcome the poor prognostic

  2013cites this paper
• Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes

  2012cites this paper
• Genetic aberrations in patients with leukaemia and their impact on prognosis

  2012cites this paper
• Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+).

  2012cites this paper
• Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia

  2011cites this paper
• Histone methyltransferases in cancer.

  2010influential citation
• Molecular characterisation of a recurrent, semi‐cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia

  2010cites this paper
• Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia

  2010cites this paper
• 7. Chronic Myeloid Leukemia

  2010cites this paper
• Array-based comparative genomic hybridization characterizes a deletion associated with a t(15;17) in acute promyelocytic leukemia.

  2008cites this paper
• Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.

  2007cites this paper
• Cancer genetics of epigenetic genes.

  2007cites this paper
• Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

  2007cites this paper
• Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.

  2006cites this paper
• Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia.

  2006cites this paper
• Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia

  2006influential citation
• Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia

  2005cites this paper
• Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

  2005cites this paper
• Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors.

  2005cites this paper
• Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9

  2005cites this paper
• Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells.

  2005cites this paper
• CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors

  2004cites this paper
• Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5.

  2004cites this paper
• A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion

  2004cites this paper
• Deletion of one copy of the p16INK4A tumor suppressor gene is implicated as a predisposing factor in pediatric leukemia.

  2004cites this paper
• Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

  2004cites this paper
• Treatment options in chronic myeloid leukemia: imatinib vs interferon

  2004cites this paper